• Reports say another federal probe into Goldman Sachs’ (NYSE:GS) handling of CDO is in the works, regarding a $2 billion Hudson Mezzanine offering sold in 2006

• Old Republic (NYSE:ORI) announced plans to merge with PMA Capital (NASDAQ:PMACA), in a $365 million deal

• Citigroup (NYSE:C) upgraded shares of Martin Marietta Materials (NYSE:MLM) to “hold” from “sell”

• Keybanc upgraded Crane (NYSE:CR) to “buy” from “hold,” with a $39 price target

• Lululemon (NASDAQ:LULU) reported better-than-projected first quarter earnings of 27 cents a share, ahead of Zacks estimates of 21 cents, on revenues of $138.3 million, which topped Zacks estimates of $129 million

• Auriga upgraded Omnicell (NASDAQ:OMCL) to “buy” from “hold,” with a $15 price target

• Human Genome Sciences (NASDAQ:HGSI) said it is seeking FDA approval of experimental lupus drug Benlysta, being co-developed with GlaxoSmithKline (NYSE:GSK)

• Keybanc reiterated its buy rating on Tenneco (NYSE:TEN) with a $36 price target and maintained its buy on FMC (NYSE:FMC) with a $71 price target

Zacks Investment Research